Lyrica Capsule 150 mg (Pregabalin)

Adult dosage

This medication is taken orally, in two divided doses per day, regardless of meals. 1. Neuropathic pain - Peripheral neuropathic pain: The starting dose is 150 mg per day, which may be increased to 300 mg after 3 to 7 days, and if necessary, may be increased up to 600 mg at 7-day intervals. - Central neuropathic pain: The starting dose is 150 mg per day, which may be increased to 300 mg after 1 week.

Children's dosage

Administration is not recommended for children under the age of 12 and adolescents aged 12-17 due to insufficient safety and efficacy data.

During treatment with this medication, suicidal thoughts or actions, symptoms of depression, and changes in mood and behavior may occur, and if such symptoms appear, you must immediately inform your doctor or pharmacist. Individuals with allergies to this medication or a history of hypersensitivity to its ingredients should not take it. In patients with diabetes, weight gain from this medication may necessitate adjustments to blood sugar control medication doses. If symptoms of angioedema like swelling around the face, mouth, or throat occur, stop taking the medication immediately and consult healthcare personnel. Elderly patients should be cautious as dizziness or drowsiness may arise from taking this medication, increasing the risk of falls or injury. Transient blurred vision or changes in vision may occur during treatment; if the symptoms persist, consult healthcare personnel. There is insufficient clinical evidence when switching from other antiepileptic medications to this drug, so careful consideration is required. Suddenly stopping this medication may result in withdrawal symptoms such as insomnia, headache, nausea, anxiety, so it should be gradually reduced following a doctor's instructions. Patients with a history of drug abuse may be at higher risk for misuse or dependence on this medication and should use it with special caution. Dosing adjustments may be necessary for patients with reduced kidney function. Patients with heart disease should consult healthcare personnel as there is a risk of developing congestive heart failure when taking this medication. Combining this medication with other central nervous system depressants, particularly opioid analgesics, may increase the risk of respiratory depression, so caution is advised. In early pregnancy, there may be a risk of congenital malformations; therefore, it should be avoided during pregnancy, and women of childbearing age should use effective contraception. During lactation, this medication may be passed into breast milk and affect the baby, so consideration should be given to stopping breastfeeding or the medication. Activities requiring concentration, such as driving or operating machinery, should only be undertaken after verifying the absence of dizziness or drowsiness post-ingestion of this medication. In case of overdose, symptoms such as drowsiness, confusion, depression, and seizures may occur, requiring immediate medical attention. This medication should be stored out of the reach of children and should not be transferred to other containers. If severe rash, red spots, or blisters appear on the skin during treatment, stop taking the medication immediately and consult healthcare personnel.

Serious side effects

• Hives
• severe swelling (edema)
• angioedema
• facial swelling
• facial paralysis (palsy)
• visual disturbances
• severe allergic reactions
• Stevens-Johnson syndrome
• toxic epidermal necrolysis
• severe skin adverse reactions

Mild side effects

• Confusion
• disorientation
• irritability
• depression
• euphoria
• decreased libido
• insomnia
• derealization
• sexual dysfunction
• restlessness

This medication should be stored in a tightly closed container to prevent air or moisture from entering, in a cool place between 15 and 30 degrees Celsius.

Appearance

Hard capsules with a white or light yellow powder inside, with a white upper and lower part.

Package unit

Bottle packaging - 30 capsules/bottle